{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26","upperLimit":"504","value":"246"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Overall Survival is defined as the interval between day of transplant and day of death.","dispersionType":"Full Range","groups":[{"description":"Fludarabine 40 mg/m\\^2 intravenous (IV) administered from Day -6 to -3, Melphalan 140 mg/m\\^2 IV on Day -2 and Alemtuzumab 50 mg IV on Day -1. Day 0 Stem Cell infusion: Fresh or cryopreserved peripheral blood progenitor cells infused. Planned Donor Lymphocyte Infusion CD3+ cells: 1 x 10\\^6 CD3+ cells/kg or 3 x 10\\^6 CD3+ cells/kg between Day +56 \\& +64. Tacrolimus 0.015 mg/kg IV as continuous infusion daily to achieve therapeutic level of 5-15 ng/ml (target 10 ng/ml). Tacrolimus changed to oral dosing, tapering approximately Day +35 to off by Day +42. Methotrexate 5 mg/m\\^2 administered IV days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning Day +7, continuing until absolute neutrophil count (ANC)\\> 500\\*10/L for 3 consecutive days.","id":"OG000","title":"Stem Cell Transplant + Donor Lymphocyte Infusion"}],"paramType":"MEDIAN","populationDescription":"Sixteen participants have been treated on study and were evaluable for treatment response. Out of 16, 7 participants met the criteria to receive planned DLI.","reportingStatus":"POSTED","timeFrame":"Every 3 months until day of death","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"days"}